NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

GSK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

GSK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February ...

Manchester-based HIV charity George House Trust has won a GSK Impact Award – one of the nation’s top healthcare charity ...

Receiving an electronic reminder about influenza vaccination appeared to decrease COVID vaccination rates. Further study of ...

Refractory chronic cough is a cough that persists for over 8 weeks and does not respond to treatment of any underlying cause. Recent randomised trials for refractory chronic cough have shown ...

The conditional approvals mean that GSK may need survival data from a larger trial to keep the drug on the market in the longer term. That data should come from an ongoing phase 3 study comparing ...

AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

The coveted designation for GSK5764227 (GSK'227, previously known as HS-20093 ... and 70% of cases have extensive-stage disease, meaning the cancer has spread throughout one or both lungs and ...

Immune responses against serogroups A, C, W, and Y were noninferior between the MenABCWY and MenACWY-CRM vaccines in young adults and adolescents.